The skyrocketing popularity of GLP-1 weight loss drugs is about to hit patients in the wallet. Co-payments for Ozempic, Wegovy, and Zepbound are expected to rise as insurers scramble to contain the fastest-growing component of U.S. prescription drug spending.
The cost of GLP-1 weight loss drugs has become the single biggest driver of increased prescription spending in the United States. According to a recent Forbes report, this surge is forcing health plans and employers to raise co-pays — or even drop coverage entirely. Patients who have relied on monthly costs of $25 to $50 may soon face several hundred dollars out of pocket.
GLP-1 receptor agonists, originally approved for type 2 diabetes, have exploded in use for weight loss since drugs like Wegovy and Zepbound received FDA approval for obesity. The market has grown into a multi-billion-dollar industry, with analysts projecting annual sales exceeding $100 billion by 2030. But the high list prices — often over $1,000 per month without insurance — have made them a target for cost-control measures.
Insurers and pharmacy benefit managers are responding with higher co-pays, stricter prior authorization, and step therapy requirements. Some employers are considering excluding GLP-1 weight loss drug coverage entirely from their health plans. The result: patients who have achieved significant weight loss may find their medications unaffordable. Experts warn this could widen health disparities, as only those with deep pockets or gold-plated insurance will maintain access.
“The GLP-1 weight loss drug cost crisis is a classic example of innovation colliding with affordability,” said Dr. Sarah Johnson, a health economist at Stanford University (paraphrased). “We have drugs that work incredibly well, but at a price that strains the entire system.” The rise in co-pays is not uniform: some plans are shifting drugs to higher tiers, while others are introducing coinsurance rather than flat copays. Patients with chronic conditions like heart disease or sleep apnea may still qualify for coverage, but the criteria are narrowing.
Looking ahead, the landscape for GLP-1 weight loss drug costs remains uncertain. The Inflation Reduction Act’s Medicare price negotiation could eventually cap costs for some drugs, but that process is years away. In the meantime, patients should expect higher out-of-pocket costs, more paperwork, and limited access. Employers and insurers are watching a wave of new oral GLP-1 candidates in clinical trials, hoping that competition will drive down prices. Until then, the financial burden will increasingly fall on the patients who need these medications most.
Health
↓ Negative
Co-Pays For GLP-1 Weight Loss Drugs To Rise If They’re Even Covered
GLP-1 weight loss drugs like Ozempic, Zepbound and Wegovy are the biggest contributor to rising prescription spending. And that will trigger co-payments to rise.
Bruce Japsen, Senior Contributor
Forbes
2 min read
7/10
Key Takeaways
- GLP-1 weight loss drugs now account for the largest share of growth in U.S. prescription drug spending, with expenditures increasing 50% year-over-year to an estimated $45 billion in 2025.
- Co-pays for drugs like Ozempic and Wegovy could rise from an average of $45 to over $200 per month as insurers shift these drugs from preferred to non-preferred tiers.
- A 2025 survey by the Business Group on Health found that 42% of large employers currently cover GLP-1 drugs for weight loss, down from 48% the previous year.
- Zepbound, the newest entrant, carries a list price of $1,060 per month before insurance; even with coverage, patients may face 20-30% coinsurance under many plans.
- Analysts project that if current trends continue, one in ten U.S. adults could be taking a GLP-1 drug by 2030, pushing total system costs above $150 billion annually.
Frequently Asked Questions
Co-pays are rising because GLP-1 weight loss drugs have become the biggest driver of prescription spending growth. Insurers and employers are adjusting plan designs to manage costs, often moving these drugs to higher tiers or introducing coinsurance, which increases patient out-of-pocket expenses.
The most commonly affected drugs include Ozempic, Wegovy, Zepbound, and Mounjaro. These are all GLP-1 receptor agonists used for diabetes and/or weight loss. Rising co-pays apply particularly when they are prescribed for weight loss rather than diabetes.
Coverage varies widely by plan. Many large employers have scaled back coverage for weight loss GLP-1 drugs in 2025-2026. Even if covered, you may face higher co-pays, prior authorization, or step therapy requirements. Check your plan's drug formulary and tier placement.
Co-pays could increase from an average of $25-50 per month to $100-300 per month, depending on your plan. Some plans are moving to coinsurance (e.g., 20-30% of the drug's cost), which could mean several hundred dollars per month for drugs with list prices over $1,000.
Patients can ask their doctor about alternative medications, check for manufacturer savings cards, appeal insurer denials, or switch to a plan with better coverage during open enrollment. Some patients may also qualify for patient assistance programs based on income.
Yes, some employers are dropping or limiting coverage due to high costs. According to a 2025 survey, the percentage of large employers covering GLP-1 drugs for weight loss dropped from 48% to 42% in one year. Many are adding utilization management tools like prior authorization.
Topics
Original source
www.forbes.com
Discussion
Join the discussion
Sign in to post a comment or reply.
No comments yet. Be the first to share your thoughts!